Published in J Med Chem on December 05, 2002
Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer (2007) 1.07
Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds. Mol Pharmacol (2006) 0.99
A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun (2005) 0.98
Structural studies of a potent insect maturation inhibitor bound to the juvenile hormone esterase of Manduca sexta. Biochemistry (2006) 0.96
Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat (2010) 0.87
Juvenile hormone esterase: biochemistry and structure. J Pestic Sci (2010) 0.87
Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH). Bioorg Med Chem (2007) 0.80
Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis. Bioorg Med Chem (2008) 0.80
Reactivity versus steric effects in fluorinated ketones as esterase inhibitors: a quantum mechanical and molecular dynamics study. J Mol Model (2010) 0.75
Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2. Bioorg Med Chem (2016) 0.75
Mass spectrometry-based metabolomics. Mass Spectrom Rev (2006) 5.23
Dioxygen activation by a dinuclear nickel thiolate complex: structural characterization of the ligand oxidized product. Chem Commun (Camb) (2003) 4.29
Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A (2005) 4.07
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension (2002) 3.66
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov (2009) 3.46
Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol (2005) 3.38
Metabolomics: building on a century of biochemistry to guide human health. Metabolomics (2005) 3.01
Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res (2004) 2.98
Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res (2005) 2.95
Regulation and function of Arabidopsis JASMONATE ZIM-domain genes in response to wounding and herbivory. Plant Physiol (2008) 2.94
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol (2002) 2.86
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension (2005) 2.76
Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol (2004) 2.59
Hydroxonium hydrate tris(2,4,6-triamino-1,3,5-triazin-1-ium) bis[bis(pyridine-2,6-dicarboxylato)manganate(II/III)] hydroxide pyridine-2,6-dicarboxylic acid solvate pentahydrate. Acta Crystallogr C (2008) 2.59
Regulation of ceramide biosynthesis by TOR complex 2. Cell Metab (2008) 2.57
Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem (2007) 2.45
Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem (2004) 2.43
Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab (2007) 2.41
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lipid Res (2002) 2.32
Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal Biochem (2005) 2.26
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci U S A (2005) 2.25
Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol (2007) 2.17
Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry (2002) 2.16
Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem (2009) 2.16
The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci U S A (2003) 2.13
The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A (2005) 2.10
A bimodal distribution of two distinct categories of intrinsically disordered structures with separate functions in FG nucleoporins. Mol Cell Proteomics (2010) 2.09
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 2.07
Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins Other Lipid Mediat (2006) 2.03
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension (2005) 2.01
Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol (2012) 2.01
Creatininium bis-(pyridine-2,6-dicarboxyl-ato)chromate(III) pyridine-2,6-dicarboxylic acid hexa-hydrate. Acta Crystallogr Sect E Struct Rep Online (2008) 2.00
The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol (2007) 1.99
Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem (2006) 1.95
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A (2006) 1.95
A rapid wound signal activates the systemic synthesis of bioactive jasmonates in Arabidopsis. Plant J (2009) 1.95
Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol (2010) 1.87
CsrA regulates translation of the Escherichia coli carbon starvation gene, cstA, by blocking ribosome access to the cstA transcript. J Bacteriol (2003) 1.82
In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens. Environ Health Perspect (2008) 1.82
Occurrence of endocrine-disrupting chemicals in indoor dust. Sci Total Environ (2008) 1.81
Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett (2006) 1.77
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol (2005) 1.76
Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res (2010) 1.76
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet (2006) 1.74
Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci (2006) 1.71
Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A (2008) 1.69
Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem (2005) 1.69
Lipoyl synthase requires two equivalents of S-adenosyl-L-methionine to synthesize one equivalent of lipoic acid. Biochemistry (2004) 1.67
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol (2009) 1.64
Triclocarban enhances testosterone action: a new type of endocrine disruptor? Endocrinology (2007) 1.63
Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol (2009) 1.60
Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci U S A (2007) 1.60
An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol (2005) 1.59
Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry (2004) 1.59
Dynamic force spectroscopy of parallel individual Mucin1-antibody bonds. Proc Natl Acad Sci U S A (2005) 1.58
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A (2002) 1.51
Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol (2009) 1.49
Polymorphisms in human soluble epoxide hydrolase. Mol Pharmacol (2003) 1.49
Photolabile ruthenium nitrosyls with planar dicarboxamide tetradentate N(4) ligands: effects of in-plane and axial ligand strength on NO release. Inorg Chem (2004) 1.47
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. J Med Chem (2010) 1.46
Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A (2011) 1.45
Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc Natl Acad Sci U S A (2011) 1.45
Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol (2008) 1.44
Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2008) 1.44
Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med (2014) 1.44
Facile ring opening of iron(III) and iron(II) complexes of meso-amino-octaethylporphyrin by dioxygen. J Am Chem Soc (2004) 1.42
Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol (2008) 1.42
Multifaceted characterization of cell wall decomposition products formed during ammonia fiber expansion (AFEX) and dilute acid based pretreatments. Bioresour Technol (2010) 1.41
The Photorhabdus Pir toxins are similar to a developmentally regulated insect protein but show no juvenile hormone esterase activity. FEMS Microbiol Lett (2005) 1.40
Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci U S A (2009) 1.40
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet (2008) 1.38
Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J Pharmacol Exp Ther (2010) 1.38
PCB-induced oxidative stress in endothelial cells: modulation by nutrients. Int J Hyg Environ Health (2002) 1.36
Metabolomics--a new exciting field within the "omics" sciences. Environ Health Perspect (2004) 1.35
Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension (2006) 1.34
A double concave hydrocarbon buckycatcher. J Am Chem Soc (2007) 1.34
Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am J Physiol Heart Circ Physiol (2004) 1.34
Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) (2009) 1.34
1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J Med Chem (2007) 1.32
A baculovirus-encoded protein tyrosine phosphatase gene induces enhanced locomotory activity in a lepidopteran host. Proc Natl Acad Sci U S A (2005) 1.32
Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension (2002) 1.32
Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids. Protein Sci (2005) 1.32
Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects. Environ Sci Technol (2011) 1.31
Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J Med Chem (2012) 1.30
Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J (2008) 1.30
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther (2011) 1.30
Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events. Proc Natl Acad Sci U S A (2010) 1.29
Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs. Eur J Pharm Sci (2010) 1.29
Purification and characterization of four beta-expansins (Zea m 1 isoforms) from maize pollen. Plant Physiol (2003) 1.28
QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J Med Chem (2003) 1.28
A sensitive class specific immunoassay for the detection of pyrethroid metabolites in human urine. Chem Res Toxicol (2004) 1.28
Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J (2008) 1.28
High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis. Anal Chim Acta (2006) 1.26
Hydroxonium hydrate tris-(2,4,6-tri-amino-1,3,5-triazin-1-ium) bis-[bis-(pyri-dine-2,6-dicarboxyl-ato)cuprate(II)] pyridine-2,6-dicarboxylic acid hexa-hydrate. Acta Crystallogr Sect E Struct Rep Online (2009) 1.26
Vascular localization of soluble epoxide hydrolase in the human kidney. Am J Physiol Renal Physiol (2003) 1.25
Microarray immunoassay for phenoxybenzoic acid using polymer encapsulated Eu:Gd2O3 nanoparticles as fluorescent labels. Anal Chem (2005) 1.24